SCHEMBL7189992

SCHEMBL7189992

CCOCCOc1cc(OCCOCC)c(PC(=O)c2c(OC)cccc2OC)c(OCCOCC)c1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
APP P05067 2/20 0.38
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
MAPK1 P28482 1/20 0.36
FFAR1 O14842 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175442 0.93 L3MBTL1 (0.42) MAPTLMNASMN1; SMN2CA12CA1
SCHEMBL7177745 0.91 APP (0.37) MAPTLMNASMN1; SMN2L3MBTL1APP
SCHEMBL7188800 0.89 CA12 (0.42) MAPTLMNASMN1; SMN2CA12CA1
SCHEMBL7187927 0.89 CA12 (0.42) MAPTLMNASMN1; SMN2CA12CA1
SCHEMBL7181299 0.88 PPARA (0.41) MAPTLMNASMN1; SMN2CA12CA1
SCHEMBL7178292 0.87 FFAR1 (0.41) MAPTLMNAL3MBTL1APPMEN1
SCHEMBL7190024 0.87 L3MBTL1 (0.43) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL7177416 0.87 PPARA (0.43) MAPTLMNAMEN1KMT2A
SCHEMBL7179890 0.87 SMN1; SMN2 (0.49) MAPTLMNASMN1; SMN2CA12CA1
SCHEMBL7187392 0.86 MAPT (0.46) MAPTLMNASMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885LMNA 3241/4885SMN1; SMN2 2939/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885LMNA 3247/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.